LAVA Therapeutics N.V. (LVTX)

NASDAQ: LVTX · Delayed Price · USD
4.94
-0.03 (-0.60%)
At close: Jan 21, 2022 3:57 PM
4.86
-0.08 (-1.62%)
After-hours:Jan 21, 2022 4:00 PM EST
Market Cap127.33M
Revenue (ttm)4.45M
Net Income (ttm)-32.90M
Shares Out25.78M
EPS (ttm)-2.87
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,568
Open5.04
Previous Close4.97
Day's Range4.86 - 5.04
52-Week Range4.22 - 17.20
Betan/a
AnalystsStrong Buy
Price Target20.81 (+321.3%)
Earnings Daten/a

About LVTX

LAVA Therapeutics N.V., a clinical-stage biotechnology company, focuses on developing its proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the potential treatment of solid tumors and hematological malignancies. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-d...

IndustryBiotechnology
IPO DateMar 25, 2021
Employees28
Stock ExchangeNASDAQ
Ticker SymbolLVTX
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for LVTX stock is "Strong Buy." The 12-month stock price forecast is 20.81, which is an increase of 321.26% from the latest price.

Price Target
$20.81
(321.26% upside)
Analyst Consensus: Strong Buy

News

LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conf...

The collective data indicate that LAVA's approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and cytokin...

3 days ago - GlobeNewsWire

CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conf...

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph shoul...

1 month ago - GlobeNewsWire

LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody...

1 month ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody...

2 months ago - GlobeNewsWire

LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium

UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that LAV...

2 months ago - GlobeNewsWire

LAVA Therapeutics Expands Management Team with Three Key Appointments

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody...

2 months ago - GlobeNewsWire

LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody...

2 months ago - GlobeNewsWire

LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences

Paul W.H.I. Parren, Ph.D., EVP, Head of R&D to share data regarding LAVA bispecific gamma delta T cell engagers derived from proprietary Gammabody™ platform Paul W.H.I. Parren, Ph.D., EVP, Head of R&D t...

2 months ago - GlobeNewsWire

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Ad...

3 months ago - GlobeNewsWire

CORRECTING and REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Ca...

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note that in the s...

3 months ago - GlobeNewsWire

LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-...

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma delta T ...

3 months ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports Second Quarter Results

Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies

5 months ago - GlobeNewsWire

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematolo...

LAVA's first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia LAVA's first-in-class gamma-delta bsTCE to be evaluat...

6 months ago - GlobeNewsWire

Ysios Capital Closes its Third Fund at €216 Million ($260 Million)

SAN SEBASTIÁN & BARCELONA, Spain--(BUSINESS WIRE)--Ysios Capital, Spain's largest and leading European venture capital firm specialised in the biotechnology sector, announces today that it has closed it...

7 months ago - Business Wire

LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T c...

7 months ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023

8 months ago - GlobeNewsWire

LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T c...

8 months ago - GlobeNewsWire

LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors

UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T...

9 months ago - GlobeNewsWire

LAVA Therapeutics Announces Pricing of Initial Public Offering

UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T...

9 months ago - GlobeNewsWire